当前位置: 首页 >> 检索结果
7945. Syndromic Surveillance for E-Cigarette, or Vaping, Product Use-Associated Lung Injury.
作者: Kathleen P Hartnett.;Aaron Kite-Powell.;Megan T Patel.;Brittani L Haag.;Michael J Sheppard.;Taylor P Dias.;Brian A King.;Paul C Melstrom.;Matthew D Ritchey.;Zachary Stein.;Nimi Idaikkadar.;Alana M Vivolo-Kantor.;Dale A Rose.;Peter A Briss.;Jennifer E Layden.;Loren Rodgers.;Jennifer Adjemian.
来源: N Engl J Med. 2020年382卷8期766-772页 7946. Vitamin E Acetate in Bronchoalveolar-Lavage Fluid Associated with EVALI.
作者: Benjamin C Blount.;Mateusz P Karwowski.;Peter G Shields.;Maria Morel-Espinosa.;Liza Valentin-Blasini.;Michael Gardner.;Martha Braselton.;Christina R Brosius.;Kevin T Caron.;David Chambers.;Joseph Corstvet.;Elizabeth Cowan.;Víctor R De Jesús.;Paul Espinosa.;Carolina Fernandez.;Cory Holder.;Zsuzsanna Kuklenyik.;Jennifer D Kusovschi.;Cody Newman.;Gregory B Reis.;Jon Rees.;Chris Reese.;Lalith Silva.;Tiffany Seyler.;Min-Ae Song.;Connie Sosnoff.;Carleen R Spitzer.;Denise Tevis.;Lanqing Wang.;Cliff Watson.;Mark D Wewers.;Baoyun Xia.;Douglas T Heitkemper.;Isaac Ghinai.;Jennifer Layden.;Peter Briss.;Brian A King.;Lisa J Delaney.;Christopher M Jones.;Grant T Baldwin.;Anita Patel.;Dana Meaney-Delman.;Dale Rose.;Vikram Krishnasamy.;John R Barr.;Jerry Thomas.;James L Pirkle.; .
来源: N Engl J Med. 2020年382卷8期697-705页
The causative agents for the current national outbreak of electronic-cigarette, or vaping, product use-associated lung injury (EVALI) have not been established. Detection of toxicants in bronchoalveolar-lavage (BAL) fluid from patients with EVALI can provide direct information on exposure within the lung.
7948. Trial of Anifrolumab in Active Systemic Lupus Erythematosus.
作者: Eric F Morand.;Richard Furie.;Yoshiya Tanaka.;Ian N Bruce.;Anca D Askanase.;Christophe Richez.;Sang-Cheol Bae.;Philip Z Brohawn.;Lilia Pineda.;Anna Berglind.;Raj Tummala.; .
来源: N Engl J Med. 2020年382卷3期211-221页
Anifrolumab, a human monoclonal antibody to type I interferon receptor subunit 1 investigated for the treatment of systemic lupus erythematosus (SLE), did not have a significant effect on the primary end point in a previous phase 3 trial. The current phase 3 trial used a secondary end point from that trial as the primary end point.
7949. NEJM Catalyst Innovations in Care Delivery - A New Journal Leading the Transformation of Health Care Delivery.
作者: Thomas H Lee.;Namita Seth Mohta.;Edward Prewitt.;Edward W Campion.;Stephen Morrissey.;Jeffrey M Drazen.;Eric J Rubin.
来源: N Engl J Med. 2020年382卷1期80-81页 7950. Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer.
作者: Dennis J Slamon.;Patrick Neven.;Stephen Chia.;Peter A Fasching.;Michelino De Laurentiis.;Seock-Ah Im.;Katarina Petrakova.;Giulia V Bianchi.;Francisco J Esteva.;Miguel Martín.;Arnd Nusch.;Gabe S Sonke.;Luis De la Cruz-Merino.;J Thaddeus Beck.;Xavier Pivot.;Manu Sondhi.;Yingbo Wang.;Arunava Chakravartty.;Karen Rodriguez-Lorenc.;Tetiana Taran.;Guy Jerusalem.
来源: N Engl J Med. 2020年382卷6期514-524页
In an earlier analysis of this phase 3 trial, ribociclib plus fulvestrant showed a greater benefit with regard to progression-free survival than fulvestrant alone in postmenopausal patients with hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. Here we report the results of a protocol-specified second interim analysis of overall survival.
7953. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.
作者: Rashmi K Murthy.;Sherene Loi.;Alicia Okines.;Elisavet Paplomata.;Erika Hamilton.;Sara A Hurvitz.;Nancy U Lin.;Virginia Borges.;Vandana Abramson.;Carey Anders.;Philippe L Bedard.;Mafalda Oliveira.;Erik Jakobsen.;Thomas Bachelot.;Shlomit S Shachar.;Volkmar Müller.;Sofia Braga.;Francois P Duhoux.;Richard Greil.;David Cameron.;Lisa A Carey.;Giuseppe Curigliano.;Karen Gelmon.;Gabriel Hortobagyi.;Ian Krop.;Sibylle Loibl.;Mark Pegram.;Dennis Slamon.;M Corinna Palanca-Wessels.;Luke Walker.;Wentao Feng.;Eric P Winer.
来源: N Engl J Med. 2020年382卷7期597-609页
Patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer who have disease progression after therapy with multiple HER2-targeted agents have limited treatment options. Tucatinib is an investigational, oral, highly selective inhibitor of the HER2 tyrosine kinase.
7954. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.
作者: Shanu Modi.;Cristina Saura.;Toshinari Yamashita.;Yeon Hee Park.;Sung-Bae Kim.;Kenji Tamura.;Fabrice Andre.;Hiroji Iwata.;Yoshinori Ito.;Junji Tsurutani.;Joohyuk Sohn.;Neelima Denduluri.;Christophe Perrin.;Kenjiro Aogi.;Eriko Tokunaga.;Seock-Ah Im.;Keun Seok Lee.;Sara A Hurvitz.;Javier Cortes.;Caleb Lee.;Shuquan Chen.;Lin Zhang.;Javad Shahidi.;Antoine Yver.;Ian Krop.; .
来源: N Engl J Med. 2020年382卷7期610-621页
Trastuzumab deruxtecan (DS-8201) is an antibody-drug conjugate composed of an anti-HER2 (human epidermal growth factor receptor 2) antibody, a cleavable tetrapeptide-based linker, and a cytotoxic topoisomerase I inhibitor. In a phase 1 dose-finding study, a majority of the patients with advanced HER2-positive breast cancer had a response to trastuzumab deruxtecan (median response duration, 20.7 months). The efficacy of trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab emtansine requires confirmation.
7957. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC.
作者: Suresh S Ramalingam.;Johan Vansteenkiste.;David Planchard.;Byoung Chul Cho.;Jhanelle E Gray.;Yuichiro Ohe.;Caicun Zhou.;Thanyanan Reungwetwattana.;Ying Cheng.;Busyamas Chewaskulyong.;Riyaz Shah.;Manuel Cobo.;Ki Hyeong Lee.;Parneet Cheema.;Marcello Tiseo.;Thomas John.;Meng-Chih Lin.;Fumio Imamura.;Takayasu Kurata.;Alexander Todd.;Rachel Hodge.;Matilde Saggese.;Yuri Rukazenkov.;Jean-Charles Soria.; .
来源: N Engl J Med. 2020年382卷1期41-50页
Osimertinib is a third-generation, irreversible tyrosine kinase inhibitor of the epidermal growth factor receptor (EGFR-TKI) that selectively inhibits both EGFR-TKI-sensitizing and EGFR T790M resistance mutations. A phase 3 trial compared first-line osimertinib with other EGFR-TKIs in patients with EGFR mutation-positive advanced non-small-cell lung cancer (NSCLC). The trial showed longer progression-free survival with osimertinib than with the comparator EGFR-TKIs (hazard ratio for disease progression or death, 0.46). Data from the final analysis of overall survival have not been reported.
|